ADMAADMA Biologics, Inc.
Price
-35%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, undemanding price, growth steady, the market undecided.
We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
ADMA Biologics, Inc. (ADMA) reported revenue of $124M in Q2 2026 (quarter ended Jun 30, 2026), up 2.0% from the same quarter a year earlier. That came with a gross margin of 69% and net income of $38M (30% of revenue). For the full year FY2025, revenue was $510M (+20% year on year) and net income $147M. Its largest segment in Q2 2026 was ADMA Bio Manufacturing at $123M, 100% of the disclosed total, well ahead of Plasma Collection Centers at 0.0%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 6, 2026ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 4, 2026On May 4, 2026, ADMA Biologics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s label expansion supplemental Biologics License Application for ASCENIV TM to include pediatric immune compromised patients two years of age and older.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $123.3MThe company’s own SEC segment disclosure.
- ADMA Bio Manufacturing$123.3M100%
- Plasma Collection Centers$30.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.